AR099475A1 - Espiro-oxazolonas - Google Patents

Espiro-oxazolonas

Info

Publication number
AR099475A1
AR099475A1 ARP150100459A ARP150100459A AR099475A1 AR 099475 A1 AR099475 A1 AR 099475A1 AR P150100459 A ARP150100459 A AR P150100459A AR P150100459 A ARP150100459 A AR P150100459A AR 099475 A1 AR099475 A1 AR 099475A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
optionally substituted
group
aryl
Prior art date
Application number
ARP150100459A
Other languages
English (en)
Inventor
Dolente Cosimo
Runtz-Schmitt Valerie
Schnider Patrick
Fasching Bernhard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR099475A1 publication Critical patent/AR099475A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1), en la que X¹ C-R¹ o N; X² C-R¹ o N; X³ C-R¹ o N; X⁴ C-R¹ o N; en el que solo uno de X¹, X², X³ y X⁴ es N o todos los X¹, X², X³ y X⁴ son C-R¹; Y es O ó S(O)ₘ; m es 0, 1 ó 2; R¹ cada uno por separado se selecciona del grupo que consiste en hidrógeno, halógeno, hidroxi, alquilo C₁₋₆- y alcoxi C₁₋₆-; R² se selecciona del grupo que consiste en H y alquilo C₁₋₆; R³ se selecciona del grupo que consiste en H y alquilo C₁₋₆; o R² y R³ juntos son =O; R⁴ se selecciona entre el grupo que consiste en i) aril-alquilo C₁₋₆-, en el que el resto arilo puede estar opcionalmente sustituido por halógeno, ii) alcoxi C₁₋₆-CH₂-, iii) alquilo C₁₋₆, iv) alquenilo C₂₋₆-CH₂-, v) alquinilo C₂₋₆-CH₂-, vi) halógeno-alquilo C₁₋₆-, vii) halógeno-alquenilo C₂₋₆-CH₂-, y viii) hidrógeno; R⁵ se selecciona entre el grupo que consiste en i) arilo-, ii) aril-alquilo C₁₋₆-, en la que el resto arilo puede estar opcionalmente sustituido por alquilo C₁₋₆, halógeno-alquilo C₁₋₆ o halógeno, y el resto alquilo C₁₋₆ puede estar opcionalmente sustituido por alquilo C₁₋₆-COO-, halógeno o hidroxi, iii) cicloalquil C₃₋₁₀-alquilo C₁₋₆-, iv) halógeno-alquilo C₁₋₆-, v) heteroaril-alquilo C₁₋₆-, en el que el resto heteroarilo puede estar opcionalmente sustituido por halógeno, vi) heterocicloalquil-alquilo C₁₋₆-, vii) alquilo C₁₋₆, viii) alquenilo C₂₋₆-CH₂- que está opcionalmente sustituido por halógeno, (alquilo C₁₋₆-)₃SiO-, alquilo C₁₋₆-COO- o alquilo C₁₋₆-OOC-, ix) alcoxi C₁₋₆-CH₂-, y x) alquinilo C₂₋₆-CH₂-, o R⁴ y R⁵ juntos se seleccionan del grupo que consiste en i) cicloalquilo C₃₋₁₀- que está opcionalmente sustituido por alquilo C₁₋₆-, alcoxi C₁₋₆, alquilo C₁₋₆-OOC-, alquilo C₁₋₆-COO-, halógeno, halógeno-alquilo C₁₋₆-, hidroxi-alquilo C₁₋₆ u oxo; ii) heterocicloalquilo que está opcionalmente sustituido por bencilo, alquilo C₁₋₆, alquilo C₁₋₆-OOC-, halógeno-alquilo C₁₋₆ u oxo; iii) cicloalquenilo C₃₋₁₀- que está opcionalmente sustituido por alquilo C₁₋₆-, alquilo C₁₋₆-OOC-, halógeno-alquilo C₁₋₆-, (alquilo C₁₋₆)₃SiO-alquilo C₁₋₆- o hidroxi-alquilo C₁₋₆-, y iv) indanilo cuando Y es SO₂; o sales farmacéuticamente aceptable de los mismos.
ARP150100459A 2014-02-20 2015-02-18 Espiro-oxazolonas AR099475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14155965 2014-02-20

Publications (1)

Publication Number Publication Date
AR099475A1 true AR099475A1 (es) 2016-07-27

Family

ID=50115765

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100459A AR099475A1 (es) 2014-02-20 2015-02-18 Espiro-oxazolonas

Country Status (12)

Country Link
US (1) US9828385B2 (es)
EP (1) EP3107916B1 (es)
JP (1) JP6480947B2 (es)
KR (1) KR20160124105A (es)
CN (1) CN105793266B (es)
AR (1) AR099475A1 (es)
CA (1) CA2929488A1 (es)
HK (1) HK1223922A1 (es)
MX (1) MX366607B (es)
RU (1) RU2016135089A (es)
TW (1) TW201600522A (es)
WO (1) WO2015124541A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
EP3523279A1 (en) 2016-10-10 2019-08-14 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators
CN109305927A (zh) * 2018-10-31 2019-02-05 抚顺顺能化工有限公司 环己酮氰醇的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433971T1 (de) * 2002-11-29 2009-07-15 Banyu Pharma Co Ltd Neue azolderivate
US20080234252A1 (en) * 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
EP2076517A1 (en) * 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
EP2104677B1 (en) * 2007-01-12 2011-12-07 F. Hoffmann-La Roche AG Spiropiperidine glycinamide derivatives
CN101801951B (zh) * 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
WO2012077655A1 (ja) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
NO3083633T3 (es) * 2013-12-19 2018-04-28
US10405278B2 (en) * 2014-10-31 2019-09-03 Qualcomm Incorporated Low power scheduling

Also Published As

Publication number Publication date
TW201600522A (zh) 2016-01-01
US9828385B2 (en) 2017-11-28
EP3107916B1 (en) 2019-03-20
WO2015124541A1 (en) 2015-08-27
MX2016009501A (es) 2016-10-26
HK1223922A1 (zh) 2017-08-11
CA2929488A1 (en) 2015-08-27
CN105793266A (zh) 2016-07-20
RU2016135089A (ru) 2018-03-23
EP3107916A1 (en) 2016-12-28
CN105793266B (zh) 2019-02-12
MX366607B (es) 2019-07-16
KR20160124105A (ko) 2016-10-26
US20160355522A1 (en) 2016-12-08
JP2017507144A (ja) 2017-03-16
JP6480947B2 (ja) 2019-03-13

Similar Documents

Publication Publication Date Title
AR104720A1 (es) Moduladores de ccr2
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR097866A1 (es) Derivados de 4-azaindol
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR101599A1 (es) Compuestos aminopirimidinilo
AR098912A1 (es) Inhibidores de syk
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR109735A1 (es) Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093804A1 (es) Derivados de pirazina agonistas de receptores cb2
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR101589A1 (es) Derivados de iminonitrilo
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos
AR102957A1 (es) Combinaciones de compuestos activos
AR101222A1 (es) Derivados de piridona
AR087771A1 (es) Moduladores de la pde10

Legal Events

Date Code Title Description
FB Suspension of granting procedure